Print page
Email page
Download PDF
« Previous Release | Next Release »
NEW HAVEN, Conn., Sep 3, 2009 (GlobeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Michael D. Kishbauch, President and Chief Executive Officer, will give a corporate presentation at the upcoming Thomas Weisel Partners Annual Healthcare Conference on Wednesday, September 9, 2009 at 2:40 p.m. EDT at the Four Seasons Hotel in Boston.
The live audio broadcasts and the subsequent archived webcasts of the Company presentation will be available on the Company's website, http://www.achillion.com, under the "News Center" section. The audio recording will be archived there for 30 days following the live presentation. Please connect to Achillion's website several minutes prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary.
About Achillion
Achillion is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The Company's proven discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease -- hepatitis, resistant bacterial infections and HIV. For more information on Achillion Pharmaceuticals, please visit the Company's website at www.achillion.com. ACHN-G
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: Achillion Pharmaceuticals, Inc.
CONTACT: Achillion Pharmaceuticals, Inc. Mary Kay Fenton (203) 624-7000 mfenton@achillion.com Lippert/Heilshorn & Associates, Inc. Investors: Anne Marie Fields (212) 838-3777 afields@lhai.com Bruce Voss (310) 691-7100 bvoss@lhai.com Media: Jules Abraham (212) 838-3777 jabraham@lhai.com
(C) Copyright 2009 GlobeNewswire, Inc. All rights reserved.
News Provided by COMTEX
